Condition: Low-risk Myelodysplastic Syndromes · Sponsor: Groupe Francophone des Myelodysplasies
Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes having failed to Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter).
This description comes directly from the study's public registry record.
Thomas CLUZEAU, MD/PhD · +33 492035839 · cluzeau.t@chu-nice.fr
Jean Baptiste MICOL, MD · jeanbaptiste.micol@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| CHU de Nice - Hôpital l'Archet - Service d'hématologie clinique | Nice, France | Not Yet Recruiting |
| Hôpital Saint Louis - Service Hématologie séniors | Paris, France | Recruiting |
| Institut Gustave Roussy - Service d'hématologie | Villejuif, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06670222